Biotech entity
Auvelity is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 1.4 stories per week across a 10-day span. They are less corroborated than the beat average, carrying 2 original sources each against 5 for the same window.
Last mentioned: Jul 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Auvelity is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 1.4 stories per week across a 10-day span. They are less corroborated than the beat average, carrying 2 original sources each against 5 for the same window. Their average consequence score of 5 runs below the beat's 6.2 for that window. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Biotech stories that mention S&P 500, published between June 28, 2026 and July 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering S&P 500. Shared-story counts are live from our verified record — not editorial picks.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
Pfizer’s 2025 GLP-1 failure underscores a faltering pipeline just as generational patent cliffs approach. The 130% dividend payout ratio highlights the financial strain of recent R&D misses, challenging the biotech giant’s turnaround narrative.
Source: Reuben Gregg Brewer (us) · fool.com
S&P 500 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
